October 7, 2021 -- PerkinElmer has received emergency use authorization (EUA) from the U.S. Food and Drug Administration (FDA) for its PKamp Respiratory SARS-CoV-2 reverse transcription polymerase chain reaction (RT-PCR) Panel 1.
Qualified laboratories can immediately begin using the RT-PCR test for the simultaneous qualitative detection and differentiation of SARS-CoV-2, influenza A, influenza B, and respiratory syncytial virus (RSV) isolated from nasopharyngeal swabs, anterior nasal swabs, and midturbinate swabs, the company said.
The PKamp Respiratory assay allows laboratories to conserve resources by avoiding multiple tests on samples collected from individuals suspected of respiratory viral infection consistent with COVID-19, PerkinElmer said.
When LabPulse gets hot new information, our Insiders are the first to find out. Stay current in today's competitive market by receiving our exclusive free email updates.Yes, Keep Me Current